Unity Biotechnology

Founded 2009 · Biotech · Defunct

UBX1325, a senolytic small molecule that selectively clears senescent cells

Claim this profile

Follows are private to you and power your alerts

Updated · unitybiotechnology.com

Sector
Biotech
Founded
2009
Latest Form D
$55M, Mar 2018
Total capital
$166M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$166M
5 Form D · last Mar 2018
103 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
24
16 pending · first 2018
Rank in peer group#71 of 1449

Capital timeline

20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $166M1st Form D$250K3rd Form D$2M4th Form D$108M5th Form D$55M
20092011201320152017FEDERAL ↑EQUITY ↓Cumulative $166M3rd Form D$2M4th Form D$108M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$55M
  • Private capital raisedForm D · SEC · 4th filing$108M
  • Private capital raisedForm D · SEC · 3rd filing$2M
  • Private capital raisedForm D · SEC · 2nd filing$500
  • Private capital raisedForm D · SEC · 1st filing$250K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#71 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Bob GoeltzExecutive OfficerNamed in SEC Form D filings
  • Camille E. SamuelsDirectorNamed in SEC Form D filings
  • Dan E. MarquessExecutive OfficerNamed in SEC Form D filings
  • Graham E. CooperDirectorNamed in SEC Form D filings
  • Jamie E. DananbergExecutive OfficerNamed in SEC Form D filings
  • John E. SmitherExecutive OfficerNamed in SEC Form D filings
Show all 14 people
  • Keith E. KleinExecutive OfficerNamed in SEC Form D filings
  • Keith LeonardExecutive Officer, DirectorNamed in SEC Form D filings
  • Kristina E. BurowDirectorNamed in SEC Form D filings
  • Nathaniel E. DavidExecutive Officer, DirectorNamed in SEC Form D filings
  • Nathaniel E. DavidExecutive Officer, DirectorNamed in SEC Form D filings
  • Paul BernsDirectorNamed in SEC Form D filings
  • Robert NelsenDirectorNamed in SEC Form D filings
  • Tamara TompkinsExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 24 granted of 40
Show all 40 patent records
  • Crossbow TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Phoenix Animal Wellness, Inc.Similar federal contract value in Biotech · null in contracts
  • NABsys IncSimilar federal contract value in Biotech · null in contracts
  • INFLAMED, INC.Similar federal contract value in Biotech · null in contracts
  • Apellis Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
  • SOLVEXA, LLCSimilar federal contract value in Biotech · null in contracts

Press

1 article · matched on company name

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .